Alaunos Therapeutics, Inc.
TCRT
Price:
$2.26
Market Cap:
$5.52M
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. Additionally, they are advancing hunTR, a platform focused on human neoantigen T-cell receptors, and mbIL-15, intended for solid tumor treatment. The company maintains strategic collaborations, including a licensing agreement with PGEN Therapeuti...[Read more]
Industry
Biotechnology
IPO Date
2005-08-24
Stock Exchange
NASDAQ
Ticker
TCRT
PE Ratio
[-1.07]
ROE
[-165.94%]
Current Ratio
[1.63]
Dividend Yield
[0%]
Enterprise Value
[5.17M]
Dividend History
The ROE as of June 2026 (TTM) for Alaunos Therapeutics, Inc. (TCRT) is -165.94%
According to Alaunos Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -165.94%. This represents a change of 250.00% compared to the average of -47.41% of the last 4 quarters.
Alaunos Therapeutics, Inc. (TCRT) Historical ROE (quarterly & annually)
How has TCRT ROE performed in the past?
The mean historical ROE of Alaunos Therapeutics, Inc. over the last ten years is -119.20%. The current -165.94% ROE has changed 39.20% with respect to the historical average. Over the past ten years (40 quarters), TCRT's ROE was at its highest in in the June 2016 quarter at 252.36%. The ROE was at its lowest in in the September 2018 quarter at -313.45%.
Average
-119.20%
Median
-110.92%
Minimum
-557.16%
Maximum
213.84%
Alaunos Therapeutics, Inc. (TCRT) ROE by Quarter and Year
Discovering the peaks and valleys of Alaunos Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 469.34%
Maximum Annual ROE = 213.84%
Minimum Annual Increase = -255.58%
Minimum Annual ROE = -557.16%
| Year | ROE | Change |
|---|---|---|
| 2025 | -193.96% | -14.48% |
| 2024 | -226.81% | -59.29% |
| 2023 | -557.16% | 469.34% |
| 2022 | -97.86% | -27.86% |
| 2021 | -135.64% | 110.28% |
| 2020 | -64.51% | -47.97% |
| 2019 | -123.98% | 99.72% |
| 2018 | -62.08% | -210.63% |
| 2017 | 56.12% | -73.76% |
| 2016 | 213.84% | -255.58% |
Alaunos Therapeutics, Inc. (TCRT) Average ROE
How has TCRT ROE performed in the past?
The current ROE of Alaunos Therapeutics, Inc. (TCRT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-325.98%
5-year avg
-242.29%
10-year avg
-119.20%
Alaunos Therapeutics, Inc. (TCRT) ROE vs. Peers
How is TCRT’s ROE compared to its peers?
Alaunos Therapeutics, Inc.’s ROE is greater than Radiopharm Theranostics Limited (-93.08%), greater than Cyclerion Therapeutics, Inc. (-62.10%), greater than Pasithea Therapeutics Corp. (-57.44%), greater than VYNE Therapeutics Inc. (-69.57%), greater than Quoin Pharmaceuticals, Ltd. (-292.33%), greater than Addex Therapeutics Ltd (-102.62%), greater than Polyrizon Ltd. (-26.12%), less than AIM ImmunoTech Inc. (261.84%), greater than XTL Biopharmaceuticals Ltd. (-26.83%), greater than Impact BioMedical Inc. (-2674.57%),
| Company | ROE | Market cap |
|---|---|---|
| -93.08% | $5.50M | |
| -62.10% | $14.07M | |
| -57.44% | $4.40M | |
| -69.57% | $10.81M | |
| -292.33% | $8.43M | |
| -102.62% | $4.65M | |
| -26.12% | $12.47M | |
| 261.84% | $1.38M | |
| -26.83% | $5.04M | |
| -2674.57% | $7.31M |
Build a custom stock screener for Alaunos Therapeutics, Inc. (TCRT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alaunos Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Alaunos Therapeutics, Inc. (TCRT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Alaunos Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Alaunos Therapeutics, Inc.'s ROE?
How is the ROE calculated for Alaunos Therapeutics, Inc. (TCRT)?
What is the highest ROE for Alaunos Therapeutics, Inc. (TCRT)?
What is the 3-year average ROE for Alaunos Therapeutics, Inc. (TCRT)?
What is the 5-year average ROE for Alaunos Therapeutics, Inc. (TCRT)?
How does the current ROE for Alaunos Therapeutics, Inc. (TCRT) compare to its historical average?